Adenosine A1 receptor

Biochemistry

A1 receptors are implicated in sleep promotion by inhibiting wake-promoting cholinergic neurons in the basal forebrain. A1 receptors are also present in smooth muscle throughout the vascular system.

The adenosine A1 receptor has been found to be ubiquitous throughout the entire body.

Signaling

Activation of the adenosine A1 receptor by an agonist causes binding of Gi1/2/3 or Go protein. Binding of Gi1/2/3 causes an inhibition of adenylate cyclase and, therefore, a decrease in the cAMP concentration. An increase of the inositol triphosphate/diacylglycerol concentration is caused by an activation of phospholipase C, whereas the elevated levels of arachidonic acid are mediated by DAG lipase, which cleaves DAG to form arachidonic acid. Several types of potassium channels are activated but N-, P-, and Q-type calcium channels are inhibited.

Effect

This receptor has an inhibitory function on most of the tissues in which it rests. In the brain, it slows metabolic activity by a combination of actions. At the neuron's synapse, it reduces synaptic vesicle release.

Ligands

Caffeine, as well as theophylline, has been found to antagonize both A1 and A2A receptors in the brain.

Agonists

• 2-Chloro-N(6)-cyclopentyladenosine (CCPA).
• N6-Cyclopentyladenosine
• N(6)-cyclohexyladenosine
• Tecadenoson ((2R,3S,4R)-2-(hydroxymethyl)-5-(6- ((R)-tetrahydrofuran-3-ylamino)-9H-purin-9-yl)-tetrashydrofuran3,4-diol)
• Selodenoson ((2S,3S,4R)-5-(6-(cyclopentylamino)-9Hpurin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide)
• Capadenoson (BAY68-4986)
• Benzyloxy-cyclopentyladenosine (BnOCPA) is an A1R selective agonist.

PAMs

• 2‑Amino-3-(4′-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene # 4e

Antagonists

;Non-selective

• Caffeine
• Theophylline
• CGS-15943

;Selective

• 8-Cyclopentyl-1,3-dimethylxanthine (CPX / 8-cyclopentyltheophylline)
• 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)
• 8-Phenyl-1,3-dipropylxanthine
• Bamifylline
• BG-9719
• Tonapofylline (BG-9928)
• FK-453
• FK-838
• Rolofylline (KW-3902)
• N-0861
• ISAM-CV202

In the heart

In the heart, A1 receptors play roles in electrical pacing (chronotropy and dromotropy), fluid balance, local sympathetic regulation, and metabolism.

When bound by adenosine, A1 receptors inhibit impulses generated in supraventricular tissue (SA node, AV node) and the Bundle of His/Purkinje system, leading to negative chronotropy (slowing of the heart rate). Specifically, A1 receptor activation leads to inactivation of the inwardly rectifying K+ current and inhibition of the inward Ca2+ current (ICa) and the 'funny' hyperpolarization-activated current (If). Adenosine agonism of A1ARs also inhibits release of norepinephrine from cardiac nerves. Norepinephrine is a positive chronotrope, inotrope, and dromotrope, through its agonism of β adrenergic receptors on pacemaker cells and ventricular myocytes.

Collectively, these mechanisms lead to an myocardial depressant effect by decreasing the conduction of electrical impulses and suppressing pacemaker cells function, resulting in a decrease in heart rate. This makes adenosine a useful medication for treating and diagnosing tachyarrhythmias, or excessively fast heart rates. This effect on the A1 receptor also explains why there is a brief moment of cardiac standstill when adenosine is administered as a rapid IV push during cardiac resuscitation. The rapid infusion causes a momentary myocardial stunning effect.

In normal physiological states, this serves as protective mechanisms. However, in altered cardiac function, such as hypoperfusion caused by hypotension, heart attack or cardiac arrest caused by nonperfusing bradycardias, adenosine has a negative effect on physiological functioning by preventing necessary compensatory increases in heart rate and blood pressure that attempt to maintain cerebral perfusion.

Metabolically, A1AR activation by endogenous adenosine across the body reduces plasma glucose, lactate, and insulin levels, however A2aR activation increased glucose and lactate levels to an extent greater than the A1AR effect on glucose and lactate. Thus, intravascular administration of adenosine increases the amount of glucose and lactate available in the blood for cardiac myocytes. A1AR activation also partially inhibits glycolysis, slowing its rate to align with oxidative metabolism, which limits post-ischemic damage through reduced H+ generation.

In the state of myocardial hypertrophy and remodeling, interstitial adenosine and the expression of the A1AR receptor are both increased. After transition to heart failure however, overexpression of A1AR is no longer present. Excess A1AR expression can induce cardiomyopathy, cardiac dilatation, and cardiac hypertrophy. Cardiac failure may involve increased A1AR expression and decreased adenosine in physical models of cardiac overload and in dysfunction induced by TNFα. Heart failure often involves secretion of atrial natriuretic peptide to compensate for reduced renal perfusion and thus, secretion of electrolytes. A1AR activation also increases secretion of atrial natriuretic peptide from atrial myocytes.

References

References

1. (March 1995). "Localization of the adenosine A1 receptor subtype gene (ADORA1) to chromosome 1q32.1". Genomics.
2. (February 2007). "Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study". The Journal of Neuroscience.
3. (March 2005). "Role of A1 adenosine receptors in regulation of vascular tone". American Journal of Physiology. Heart and Circulatory Physiology.
4. (December 2001). "International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors". Pharmacological Reviews.
5. (May 2011). "Adenosine and its receptors in the heart: regulation, retaliation and adaptation". Biochimica et Biophysica Acta (BBA) - Biomembranes.
6. (July 2022). "Selective activation of Gαob by an adenosine A₁ receptor agonist elicits analgesia without cardiorespiratory depression". Nature Communications.
7. (September 2014). "Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene". Journal of Medicinal Chemistry.
8. (March 2002). "BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy". Circulation.
9. (August 2007). "Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study". Journal of the American College of Cardiology.
10. (October 2007). "The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance". Journal of the American College of Cardiology.
11. (October 2008). "The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment". Journal of Cardiac Failure.
12. (February 2022). "Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A₁ Antagonists". Journal of Medicinal Chemistry.
13. (March 1995). "Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes". FASEB Journal.
14. (November 2004). "Receptors subtypes involved in adenosine-mediated modulation of norepinephrine release from cardiac nerve terminals". Canadian Journal of Physiology and Pharmacology.
15. (May 2020). "Fast in vivo detection of myocardial norepinephrine levels in the beating porcine heart". American Journal of Physiology. Heart and Circulatory Physiology.
16. (June 2004). "Beyond Bowditch: the convergence of cardiac chronotropy and inotropy". Cell Calcium.
17. (March 2009). "Adenosine A1 and A2a receptors modulate insulinemia, glycemia, and lactatemia in fetal sheep". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology.
18. (September 1999). "Alteration of glycogen and glucose metabolism in ischaemic and post-ischaemic working rat hearts by adenosine A1 receptor stimulation". British Journal of Pharmacology.
19. (June 2001). "Heteromeric association creates a P2Y-like adenosine receptor". Proceedings of the National Academy of Sciences of the United States of America.
20. (July 2000). "Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes". Proceedings of the National Academy of Sciences of the United States of America.
21. (February 2007). "Adenosine A1 receptor expression during the transition from compensated pressure overload hypertrophy to heart failure". Journal of Hypertension.
22. (November 2006). "Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function". Circulation.
23. (May 2007). "A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction". Circulation.
24. (December 2008). "Stimulation of ANP secretion by 2-Cl-IB-MECA through A(3) receptor and CaMKII". Peptides.
25. (December 2005). "Adenosine-stimulated atrial natriuretic peptide release through A1 receptor subtype". Hypertension.